With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

De­spite a big lead in pul­monary ar­te­r­i­al hypterten­sion, Unit­ed Ther­a­peu­tics is un­der the gun as it looks to stave off com­peti­tors and build a suc­cess­ful ex­pan­sion over in on­col­o­gy. So far, those re­sults have been mixed. But now, Unit­ed is on the cusp of adding a new for­mu­la­tion to its suc­cess­ful Ty­va­so fran­chise that could spur growth.

For a cool price tag of $105 mil­lion, Unit­ed Ther­a­peu­tics has snared a pri­or­i­ty re­view vouch­er (PRV) for rare pe­di­atric dis­eases from Y-mAbs Ther­a­peu­tics that it in­tends to use to help take an in­haler ver­sion of its hy­per­ten­sion med Ty­va­so across the fin­ish line, the com­pa­ny said Mon­day. The vouch­er was orig­i­nal­ly in­tend­ed for Y-mAbs’ ap­pli­ca­tion for Danyelza in neu­rob­las­toma and wasn’t used for the FDA’s ap­proval in No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER